Abstract:Objective:To investigate the role of anti-Müllerian hormone (AMH) on the ovarian function evaluation in premenopausal breast cancer patients with hormone receptor positive after different courses of ovarian function suppression (OFS) treatment.Methods:This study was a two-way cohort study. The main endpoints of the study were menstrual recovery and hormone changes after OFS treatment. Totally sixty-seven premenopausal breast cancer patients were enrolled, whose estrogen receptor (ER) and progesterone receptor (PR) had been tested positive from May 2015 to May 2019, and who had undergone operations, chemotherapies and OFS treatments for 24-60 months in Fudan University Shanghai Cancer Center. Twelve cases were eliminated because of missing tracking. The enrolled cases were divided into 2 groups according to OFS treatment, group A was treated with goserelin for 24 months ( n=32), and group B, with goserelin for 25-60 months ( n=23). Following the OFS treatment, the time points of menstrual recovery were observed and the serum levels of AMH, follicle-stimulating hormone (FSH) and estrogen (E 2) levels were measured in the two groups. Results:The follow-up period of the two groups was (42.0±12.3) months. All the patients survived their follow-ups, except one who developed recurrence and metastasis in the 25-60 month course of OFS. No significant differences were observed in age, height, weight, body mass index (BMI), menarche age, pathological type, pathological grade, ER, PR positive rate, human epidermal growth factor receptor-2 (HER-2) positive rate, sequence of chemotherapy and OFS treatment between the two groups (all P>0.05). The time of menstruation recovery was longer in group A than in group B, the menstruation recovery rate became lower, and the regular rate of menstruation became lower, but there was no significant difference (all P>0.05). After the completion of OFS treatment, the change of AMH and FSH levels in the second year was significantly different from that in the first year ( P=0.003, P=0.004), and the change of AMH and E 2 levels was statistically different between the third year and the second year ( P=0.045, P=0.003). Compared with group B, the serum AMH levels of group A showed decrease after 1, 2 and 3 years, respectively [(0.53±0.15) μg/L vs. (1.01±0.4) μg/L; (0.91±0.25) μg/L vs. (1.38±0.57) μg/L; (1.07±0.23) μg/L vs. (1.55±0.64) μg/L]. Compared with the 1-year serum AMH levels, those of 2-year and 3-year increased 51.5% and 72.1%, respectively. In group A, the serum AMH levels increased 71.7% and 101.9%, respectively, after 2 and 3 years. In group B, the serum AMH levels increased 36.6% and 53.5%, respectively, after 2 and 3 years. The serum E 2, FSH levels were higher or lower in group A than in group B after 1,2, 3 years, showing no significant difference ( P>0.05). Additionally, the differences in serum E 2 levels were statistically significant after 2 years of OFS treatment ( U=520.51,P=0.009). Compared with the 1-year serum E 2 levels, those of 2-year and 3-year decreased 14.8% and increased 59.1%, respectively. In group A, the serum E 2 levels decreased 29.4% and increased 67.6%, respectively, after 2 and 3 years. In group B, the serum E 2 levels decreased 4.4% and increased 52.5%, respectively, after 2 and 3 years. Compared with the 1-year serum FSH levels, those of 2-year and 3-year increased 44.7%, 41.6%, respectively. In group A, the serum FSH levels increased 41.1%, 44.3%, respectively, after 2 and 3 years. In group B, the serum FSH levels increased 48.6%, 47.0%, respectively, after 2 and 3 years. Conclusion:Compared with E 2 and FSH, AMH is more likely to be a used clinically to evaluate the ovarian reserve of breast cancer patients. There is no statistical difference in different OFS courses on the ovarian function of premenstrual breast cancer patients. The ovarian function of patients with the short OFS courses could recover more quickly than those with the long OFS courses. It was necessary to monitor the E 2 levels regularly during OFS treatment.

Pretreatment Anti-Mullerian Hormone to Predict for Resumption of Mense in One Year after Chemotherapy in Premenopausal Hormone-Receptor Positive Early Breast Cancer.

Two-year Follow-Up of Pretreatment Anti-Mullerian Hormone (AMH) to Predict for Resumption of Mense after Chemotherapy in Premenopausal Hormone-Receptor (HR+) Positive Early Breast Cancer (Ebc).

Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer

Predictive Value of the Serum Anti-Müllerian Level for Spontaneous Pregnancy in Women after Endometriosis Surgery

Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer

Can Anti-Müllerian Hormone Be a Reliable Biomarker for Assessing Ovarian Function in Women Postchemotherapy?

Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study

Role of Anti-Müllerian Hormone and Testosterone in Follicular Growth: a Cross-Sectional Study.

The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer

AMH as an ovarian function predictor in premenopausal female breast cancer patients receiving chemotherapy is effective only for those over 35 years old

GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer

Post-treatment anti-Mullerian hormone (AMH) levels predict long-term ovarian dysfunction in women with hematological malignancies

Anti-Müllerian hormone as a new marker of the individualized ovarian function suppression treatment for premenopausal breast cancer patients: a cohort study

Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor

[Anti-Müllerian Hormone As a New Marker of the Ovarian Reserve Function Preservation by Goserelin During (neo)adjuvant Chemotherapy for Young Breast Cancer Patients].

Effect of chemotherapy on ovarian reserve in premenopausal patients with breast cancer

Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).

Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer

Observation and Clinical Significance of Adjuvant Chemotherapy-Induced Amenorrhea in Pre-Menopausal Breast Cancer Patients

Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy

Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer